Industrial Bank
VC Fund
Foochow, China
Industrial Bank is a VC fund in Foochow focused on Manufacturing and Battery. Founded in August 1988 and headquartered in Fuzhou, Fujian Province, Industrial Bank (IB) is one of the first batch of joint-stock commercial banks approved by the State Council and the People's Bank of China, and the first Equator Bank in China. On February 5, 2007, IB was listed on Shanghai Stock Exchange (Stock Code: 601166) . At present,with a registered capital of 19.052 billion yuan, IB has become a national joint-stock commercial bank with sound governance, distinctive characteristics, great strength and quality service, staying stably among Global Top 50 Banks.The business scope of IB includes: taking deposits; granting short, middle and long-term loan; handle domestic and overseas settlement; handle documents acceptance and discount; issue financial bonds; issue, cash and sell government bonds as agent; trade government bonds and financial bonds; issue securities other than stocks as agent; trade securities other than stocks by itself or as agent; assets custody; inter-banking borrowing/lending; trade foreign exchange by itself or as agent; purchase or sell exchange; banking card business; L/C service and guarantee; agency collection and payment and insurance; safe deposit box; financial consultant, credit inquiry, consulting and witness; and other business as approved by Chinese banking regulators.
- Total investments:
- 21
- Last investment:
- Lead investor:
- 24%
Last updated:
For AI agents: llms.txt
Industries Industrial Bank invests in
Stages Industrial Bank invests in
Countries Industrial Bank invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Jian Li
|
|||
|
Renjie Li
|
|||
3 more contacts available
Investment Focus
Industry
- Manufacturing 6 (29%)
- Battery 3 (14%)
- Biotechnology 3 (14%)
- Semiconductor 3 (14%)
- Biopharma 2 (10%)
Stage
- Series C 8 (38%)
- Debt Financing 4 (19%)
- Series B 3 (14%)
- Post-IPO Debt 2 (10%)
- Series A 1 (5%)
Country
- China 16 (76%)
- United States 2 (10%)
- South Korea 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Jian Li
Financial Director and General Manager, Planning & Financial Department
|
Financial Director and General Manager, Planning & Financial Department | Total investments: 0 | Find email | |
|
Renjie Li
President and Director
|
President and Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Weiyuan Synthetic Biotechnology
|
Weiyuan Synthetic Biotechnology specializes in the manufacturing of food, feed and materials based on synthetic biology technology. | Debt Financing / May 13, 2026 | |
|
Orbital Time
|
Orbital Space Technology develops computing satellites launched into dawn-dusk orbits to create space-based data centers. These provide continuous computing power services to customers, leveraging constant sunlight for reliable solar energy and minimal eclipses. | $8.5B / Debt Financing / Apr 20, 2026 | |
|
Jiangbei Biopharmaceuticals
|
Jiangbei Biopharmaceuticals is a wholly state-owned public service platform committed to providing an integrated laboratory information service system. | Series A / Apr 01, 2026 | |
Xinshinuo Semiconductor
|
Xinshinuo Semiconductor is a domestic semiconductor equipment and technology company. | $70.9M / Venture - Series Unknown / Dec 15, 2025 | |
Zai Lab
|
Zai Lab is an innovative biopharmaceutical company based in Shanghai focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world.Since their founding in 2014, their experienced team has secured partnerships with leading global biopharma companies, generating a broadpipeline of innovative drug candidates.They see theirselves as the trusted partner of choice for global biopharmaceutical companies seeking to access the Chinese market. Leveraging their team’s extensive global drug development expertise, combined with their demonstrated understanding of the pharmaceutical industry, the increasingly favorable clinical and regulatory environment in China and their in-house manufacturing capabilities, they plan to continue to secure relationships with global pharmaceutical companies to further expand their pipeline and foster innovation in China.Their team is passionate about bringing transformative new medicines to patients. Their vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing their partner’s and their own products in China and around the world. To that end, they have built manufacturing capabilities to support the clinical and commercial production of their drug candidates in China, and they expect to have further clinical production capabilities in the near future. Their team is planning to establish a specialized commercial team to support marketing of their products in China and beyond, and they are expanding their discovery efforts both internally and through collaborations with leading academic institutions. | $42.1M / Post-IPO Debt / Oct 16, 2025 | |
Vanke
|
\Vanke has become a real estate company in China since it stepped into the housing market over thirty years ago in 1988, with its main business being real estate development and property service. Adopting the strategy of focusing on city clusters, Vanke has covered 66 cities in mainland China by the end of 2015, mainly in the Pearl River Deltacentered on cities of Guangzhou and Shenzhen, the Yangtze River Delta centered on Shanghai, the Bohai Rim Region centered on Beijing, and the Chengdu Region which covers major cities in Midwest China. Since 2013, Vanke made its attempts to invest overseas. It has now been involved in Dozens of real estate development projects in Hong Kong, Singapore, San Francisco, New York City and London. | $194.5M / Post-IPO Debt / Mar 20, 2024 | |
Semitech
|
Semitech is an intelligent manufacturing system supplier focused on providing integrated manufacturing solutions for high-tech industries. | Series C / Jan 30, 2024 | |
uBriGene
|
Ubrigene is driven by the advancement of gene and cell therapy technologies through research and development represented by AAV vectors. It can provide a comprehensive solution for gene therapy industrialization. | $14.7M / Series C / Dec 23, 2022 | |
Hooenergy
|
Hooenergy is a provider of car charging solutions for electric vehicle users. | Debt Financing / Dec 14, 2022 | |
|
Vital Thin Film Materials
|
Pioneer Thin Film Materials Co., Ltd. is a subsidiary of Pioneer Group, dedicated to R&D, production, sales and recycling of sputtering targets and evaporation materials for vacuum coating. The product series includes targets, ingots, granules and powders made of high-purity metals, alloys, precious metals and ceramic materials, which arewidely used in display, photovoltaic, semiconductor, precision optics, data storage and glass and other fields. | $625M / Series B / Sep 28, 2022 | |
| See all 21 investments → | |||
Co-Investors
Bank of China
4 deals together
China CITIC Bank
3 deals together
Bank of Communications
2 deals together
China Construction Bank
2 deals together
China Zheshang Bank
2 deals together
Huagai Capital
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Industrial Bank invest in?
Industrial Bank invests primarily in Manufacturing, Battery and Biotechnology startups, most often at Series C and Debt Financing stage. Most of the 21 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Industrial Bank?
Public channels for Industrial Bank include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Industrial Bank?
The team at Industrial Bank includes Jian Li (Financial Director and General Manager, Planning & Financial Department) and Renjie Li (President and Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
